[go: up one dir, main page]

KR940003564A - 특정 질환의 예방 및 치료용 약제를 제조하기 위한 c1- 불활성제화제의 용도 - Google Patents

특정 질환의 예방 및 치료용 약제를 제조하기 위한 c1- 불활성제화제의 용도 Download PDF

Info

Publication number
KR940003564A
KR940003564A KR1019930016325A KR930016325A KR940003564A KR 940003564 A KR940003564 A KR 940003564A KR 1019930016325 A KR1019930016325 A KR 1019930016325A KR 930016325 A KR930016325 A KR 930016325A KR 940003564 A KR940003564 A KR 940003564A
Authority
KR
South Korea
Prior art keywords
prevention
treatment
surgery
ooou
capillary leakage
Prior art date
Application number
KR1019930016325A
Other languages
English (en)
Other versions
KR100290753B1 (ko
Inventor
아이셀레 베른트
델보스 울리히
예셀 안드레아스
Original Assignee
스타인, 하아스
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스타인, 하아스, 베링베르케 아크티엔게젤샤프트 filed Critical 스타인, 하아스
Publication of KR940003564A publication Critical patent/KR940003564A/ko
Application granted granted Critical
Publication of KR100290753B1 publication Critical patent/KR100290753B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 심한 화상(burns 또는 Scalds), 다외상, 칙외 순환의 상태에서의 수술, 시토킨, 내인성 조정기, 조정기 하이브리드 및 유전 공학에 의해 제조된 성장 인자를 사용할 경우 모세혈관 누출 증상(전신적 일헐(extravasation)) 및 순환쇼크(고질적 저혈압) 및 치료적 또는 예방적 징후를 나타내는 골수 이식 수술시간의 정맥-폐쇄 질환의 예방 및 치료용 약제를 제조하기 위한 Cl-불활성화제의 용도에 관한 것이다.

Description

특정 질환의 예방 및 치료용 약제를 제초하기 위한 Cl -불활성화제의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. 심한 화상(burns또는Scalds), 다외상, 체회순환의 상태에서의 수술, 시토킨, 내인성 조정기, 조정기 하이브리드 및 유전 공학에 의해 제조된 성장 인자를 사용할 경우 모세혈관 눅출증상(전신적 일헐(extravasation)및 순환 쇼크(고질적 저혈압) 및 치료적 또는 예방적 징후를 나타내는 골수 이식 수술시 모세혈관 누출 증상 및 간의 정맥-궤쇄 질환의 예방 및 치료용 약제를 제조하기 위한 Cl-불즐성화제의 용도.
  2. 제1항에 있어서, Cl-불존성화제를 1일 체중 1kg당 1내지 5, OOOU, 바람직하게는 5내지 1,070u를 함유하는 조성물을 제조하는 용도.
  3. 제1항에 있어서, Cl-불활성화제를 1일 체중 Ik9당 1내지 300,OOOU, 바람직하게는 50내지 60,000를 함유하는 고체 조성물을 제조하는 용도.
  4. 제1항에 있어서, 정맥내, 근육내 및 피하용 조성물을 바람직하게는 약제학적 보조제와함께 제조하는 용도.
  5. 제4항에 있어서, 경구 또는 직장용 조성물을 제조하는 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930016325A 1992-08-24 1993-08-23 C1-불활성화제를포함하는약제학적조성물 KR100290753B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4227762A DE4227762A1 (de) 1992-08-24 1992-08-24 Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten
DEP4227762.0 1992-08-24

Publications (2)

Publication Number Publication Date
KR940003564A true KR940003564A (ko) 1994-03-12
KR100290753B1 KR100290753B1 (ko) 2001-09-17

Family

ID=6466096

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930016325A KR100290753B1 (ko) 1992-08-24 1993-08-23 C1-불활성화제를포함하는약제학적조성물

Country Status (9)

Country Link
US (1) US5939389A (ko)
EP (1) EP0586909A3 (ko)
JP (1) JPH06157343A (ko)
KR (1) KR100290753B1 (ko)
AU (1) AU671287B2 (ko)
CA (1) CA2104636C (ko)
DE (2) DE4244735A1 (ko)
IL (1) IL106776A0 (ko)
NO (1) NO933000L (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4244735A1 (de) * 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
EP0868191A1 (en) * 1995-12-18 1998-10-07 Stichting Sanquin Bloedvoorziening Potentiation of complement and coagulation inhibitory properties of c1-inhibitor.
US20040152635A1 (en) * 1998-06-22 2004-08-05 Albrecht Groner Modified C1 esterase inhibitor for blocking the infectiousness of HIV
DE19827750C1 (de) 1998-06-22 1999-07-29 Centeon Pharma Gmbh Verfahren zum Abtrennen von HIV aus einer Flüssigkeit
ATE382635T1 (de) * 2000-01-31 2008-01-15 Pharming Intellectual Pty Bv Humaner c1 inhibitor hergestellt in der milch transgener säugetiere
AU2006203549B2 (en) * 2000-01-31 2008-10-09 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
HUE052154T2 (hu) 2003-05-16 2021-04-28 Pharming Intellectual Property B V Rövid felezési idejû C1 inhibitor tranziens kezeléshez
EP2698166B1 (en) 2006-10-10 2015-09-30 Regenesance B.V. Complement inhibition for improved nerve regeneration
DK2758076T3 (en) 2011-09-24 2019-04-01 Csl Behring Gmbh COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR
KR102022231B1 (ko) 2011-12-22 2019-09-19 체에스엘 베링 게엠베하 중추 신경계의 2차 부종을 치료하기 위한 ｃ1-억제제의 용도
WO2014131865A1 (en) * 2013-02-28 2014-09-04 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
KR102403299B1 (ko) 2013-03-08 2022-06-03 체에스엘 베링 게엠베하 원격 허혈-재관류 손상의 치료 및 예방
PL3013366T3 (pl) 2013-06-28 2022-01-17 Csl Behring Gmbh Terapia skojarzona z zastosowaniem inhibitora czynnika xii i inhibitora c1
EP3302529A4 (en) 2015-06-03 2019-02-06 The Children's Hospital Medical Center COMPOSITIONS AND METHODS FOR TREATING GALLENA GANGATRESIA IN NEWBORNS
AU2017305856B2 (en) 2016-08-05 2024-09-12 Csl Behring Gmbh Pharmaceutical formulations of C1 esterase inhibitor
EP3504648A1 (en) 2016-08-23 2019-07-03 CSL Behring GmbH Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
EP3681517B1 (en) 2017-09-15 2024-05-08 Cedars-Sinai Medical Center C1 esterase inhibitors for use in improving organ function in organ transplant patients
KR20230110563A (ko) 2020-11-20 2023-07-24 체에스엘 베링 게엠베하 항체 매개 거부 반응의 치료 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
US5271931A (en) * 1988-09-14 1993-12-21 The Scripps Research Institute Methods for increasing C1 inhibitor concentrations using interferon-gamma and/or interleukin-6
US5030578A (en) * 1989-07-10 1991-07-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Process for the purification of C1-inhibitor
ATE146970T1 (de) * 1990-10-16 1997-01-15 John Lezdey Behandlung von entzündungen
WO1992022320A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE4227735C2 (de) * 1992-08-21 1995-10-12 Leybold Ag Anordnung zum berührungslosen Messen der Dicke von Schichten
DE4244735A1 (de) * 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen

Also Published As

Publication number Publication date
EP0586909A3 (de) 1995-04-05
EP0586909A2 (de) 1994-03-16
CA2104636A1 (en) 1994-02-25
DE4227762A1 (de) 1994-03-03
KR100290753B1 (ko) 2001-09-17
JPH06157343A (ja) 1994-06-03
CA2104636C (en) 2003-11-11
IL106776A0 (en) 1993-12-08
AU671287B2 (en) 1996-08-22
US5939389A (en) 1999-08-17
DE4244735A1 (de) 1994-03-31
NO933000L (no) 1994-02-25
NO933000D0 (no) 1993-08-23
AU4477893A (en) 1994-03-03

Similar Documents

Publication Publication Date Title
KR940003564A (ko) 특정 질환의 예방 및 치료용 약제를 제조하기 위한 c1- 불활성제화제의 용도
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
HK1048106A1 (zh) 用於治療青光眼或眼壓過高的前列腺素衍生物
IL75851A (en) Pharmaceutical composition comprising xanthine derivatives and o-acetyl-salicylic acid or its pharmacologically tolerated salts and its preparation
KR0141913B1 (en) Anti-virus agents
DE69930271T8 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
Akpek et al. Epidural anesthesia for renal transplantation: a preliminary report
PT920865E (pt) Utilizacao de ""norastemizole"" para o tratamento de disturbios alergicos
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
SE8105561L (sv) Anvendning av pyridoxin-alfa-ketoglutarat vid profylax av hypermjolksyraemi
KR950703527A (ko) 프로스타글란딘 유도체
EP0459377B1 (en) Use of E1 prostaglandin to cure male erectile inpotence
CA1217717A (en) Pharmaceutical composition containing a fibrinolytic agent and a diffusion factor, useful for the treatment of the myocardium infarction
TR200103144T2 (tr) Yeni bileşikler
KR890012942A (ko) 5-치환된 오르니틴 유도체
KR950702544A (ko) 비페닐메탄 유도체 및 이를 함유하는 약제
RU94042230A (ru) Производные 1,3,4-оксадиазол-2-(3н)-она, их приготовление и применение в терапии
KR960701657A (ko) 피부 상처 치료용 인자 XIII (Factor XIII for treatment of skin wounds)
KR980002033A (ko) 트리아졸 유도체 또는 그 염
KR910000142A (ko) 신경보호제로서의 5-페닐-2- 푸란 에스테르, 아미드 및 케톤의 신규한 용도
KR970064604A (ko) 벤조피란 유도체 및 그의 심장질환 치료제로서의 용도
US2592149A (en) Therapeutic preparation comprising benzyl cinnamate and vitamin a
US2676961A (en) Procaine-penicillin preparation
KR920702676A (ko) 신규 입체이성질체
KR890009936A (ko) 그리세올산 모노에스테르류, 이의 제조방법 및 용도

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19930823

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 19980217

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19980508

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19930823

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20000323

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20001206

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20010306

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20010307

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20040219

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20050225

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20060223

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20070223

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20080225

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20090225

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20100223

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20110210

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20120220

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20130220

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20130220

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20140223

Termination category: Expiration of duration